Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.
Pharmacogenomics J
; 20(1): 136-158, 2020 02.
Article
en En
| MEDLINE
| ID: mdl-31616044
Colorectal cancer is one of the leading causes of cancer death worldwide. Over the last decades, several studies have shown that tumor-related genomic alterations predict tumor prognosis, drug response, and toxicity. These observations have led to the development of several therapies based on individual genomic profiles. As part of these approaches, pharmacogenomics analyses genomic alterations which may predict an efficient therapeutic response. Studying these mutations as biomarkers for predicting drug response is of a great interest to improve precision medicine. We conduct a comprehensive review of the main pharmacogenomics biomarkers and genomic alterations affecting enzyme activity, transporter capacity, channels, and receptors; and therefore the new advances in CRC precision medicine to select the best therapeutic strategy in populations worldwide, with a focus on Latin America.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Farmacogenética
/
Neoplasias Colorrectales
/
Biomarcadores de Tumor
/
Redes Reguladoras de Genes
/
Frecuencia de los Genes
Límite:
Humans
Idioma:
En
Revista:
Pharmacogenomics J
Asunto de la revista:
BIOLOGIA MOLECULAR
/
FARMACOLOGIA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Ecuador
Pais de publicación:
Estados Unidos